Tests tirzepatide to see if it changes alcohol drinking in adults
Tests weekly tirzepatide injections against placebo in adults with alcohol use disorder and excess weight.
Key facts
- Who runs it
- University of Southern California
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Registry title
- Tirzepatide for Alcohol Use Disorder
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 42 people, planned
- Started
- 6 Oct 2025
- Planned end
- 31 Aug 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Tirzepatide
- Placebo injections
- Record updated
- 14 October 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 21 to 65 with alcohol use disorder and overweight or obesity who want help to cut down or stop drinking. It tests weekly tirzepatide against placebo.
- Age
- 21 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Alcohol use disorder in the past year, at least moderate (4 or more symptoms), with a body mass index of 27 kg/m2 or more. Heavy drinking: at least 40 g a day for women or 60 g a day for men in the 28 days before the start.
- Earlier treatment
- Cannot join if in the past 3 months they had alcohol treatment, weight loss medicines, or medicines that reduce drinking (such as naltrexone or topiramate). No tirzepatide or GLP-1RA treatment in the past 6 months.
- Biomarker or test result
- HbA1C must be under 6.5% (48 mmol/mol). Kidney function (eGFR) must be 60 or higher.
Main reasons for not taking part
- Another substance use disorder, except tobacco or mild cannabis
- Type 1 or type 2 diabetes, or a history of pancreatitis
- History of significant alcohol withdrawal (such as seizure or delirium tremens)
- Known liver disease, or liver tests above 3 times the upper limit of normal
- Currently pregnant or nursing
The registry criteria, word for word
Show all 34 criteriaShow less
Who can take part
- Meeting past-year DSM-5 criteria for AUD with at least moderate severity (≥ 4 symptoms)
- Average daily consumption of ≥40g (women) / ≥ 60 g (men) per day in the 28 days prior to baseline
- Body mass index ≥ 27kg/m2
- Willingness to attend weekly medication visits and complete all study procedures
- Ability to read and communicate in English
- Age 21-65
- Treatment-seeking (i.e., currently seeking assistance to reduce or stop drinking)
- Stable housing status
Who cannot take part
- Recent (past 30 day) self-report of illicit drug use (excluding cannabis) or non-prescribed opioids; or positive urine screen for illicit drugs. A positive screen for opioids will be allowed if the participant is prescribed an opioid replacement therapy medication and can provide documentation
- Evidence of a significant anxiety or depressive disorder that is currently interfering with daily functioning, based on GAD-7 and PHQ-9 scores and physician judgement. (Anxiety or depression are not exclusionary if symptoms are stable/non-interfering with daily activities, or if the participant is receiving treatment, i.e., psychiatric medications have not changed for at least 3 months prior to baseline)
- Weight loss > 5% in the 30 days prior to screening
- Currently enrolled in another clinical trial involving an investigational product
- Current co-habitation with a person taking GLP-1RA therapy
- Planned surgical procedures requiring anesthesia within 90 days post-entry into the study
- History of treatment with tirzepatide or a GLP-1RA within 6 months of screening
- Treatment with any weight loss medications (e.g., orlistat, bupropion-naltrexone) or medications known to reduce alcohol consumption (e.g., naltrexone, topiramate, acamprosate, varenicline) in the past 3 months
- Use of prescribed or non-prescribed medications that would preclude safe use of tirzepatide in the judgement of the study physicians
- Known bone, muscle, or wasting conditions (e.g., osteoporosis, sarcopenia) aa. Presence of significant or uncontrolled GI conditions (e.g., GERD) that would interfere with treatment in the judgement of study physicians bb. Any other significant disease, disorder, or finding that in the opinion of the investigator(s) may increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data; cc. Currently pregnant or nursing, or inability to adhere to a reliable method of birth control (applies to female participants of childbearing age) dd. Uncontrolled hypertension at baseline, as indicated by an average blood pressure reading of >180/110 after three successive readings ee. History of heart attack or stroke in the 6 months prior to screening ff. A pre-treatment reduction in alcohol consumption to < 40g/day (males) or <20g/day (females) in the interval between baseline screening and randomization
- Meeting past-year DSM-5 criteria for another substance use disorder (except tobacco use disorder or mild cannabis use disorder)
- History of significant alcohol withdrawal, as indicated by history of seizure, delirium tremens; history of hospitalization for withdrawal-related symptoms; a CIWA score >9 at assessment; or a baseline score 4+ on the Prediction of Alcohol Withdrawal Severity (PAWS) scale
- History of chronic or acute pancreatitis
- History of suicide attempt or report of current (past 2 weeks) active suicidal ideation
- Lifetime diagnosis of severe mental illness (e.g., psychosis or bipolar disorder)
- Treatment for eating disorder in the past 12 months
- Report of significant medical, neurological, or psychiatric illness that would preclude safe or full study participation based on the judgement of the study physicians
- History of known liver disease
- History of malignant neoplasms in the last 5 years, except for non-melanoma skin cancer
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) type I or type II
- History of Type 1 or Type 2 diabetes, or diabetes-related conditions (e.g., diabetic retinopathy), or baseline HbA1C ≥ 6.5%
- Elevated serum lipase, amylase, bilirubin, or ALP, ALT, or AST (>3x upper limit of normal range)
- Estimated glomerular filtration rate (eGFR) <60 (indicated impaired kidney function)
- Recent (past 3 months) engagement in behavioral or pharmacological alcohol use treatment or currently mandated to receive treatment
- Inability to attend weekly clinic visits as scheduled (i.e., based on travel or work schedule)
- Current contact or co-habitation with a current or former participant in the present trial
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 65 years old?
Where in United States
- Keck School of Medicine, University of Southern CaliforniaLos Angeles, United StatesContact: Tom GilmoreTaking people
About the trial
What the trial wants to find out
The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or obesity.
The 2 groups in the trial
- TirzepatideTreatment being tested
- PlaceboPlacebo, for comparison
Treatment: Placebo injections
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase II Evaluation of Tirzepatide in Adults With Alcohol Use Disorder and Overweight or Obesity
- Plain-language title
- Tests tirzepatide to see if it changes alcohol drinking in adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06994338, who can take part
- Record updated
- 14 October 2025